Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Stoke Therapeutics, Inc. < Previous 1 2 Next > Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome September 10, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer September 04, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present at Upcoming Investor Conferences in September September 03, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome September 03, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) August 16, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates August 07, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 16, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 18, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present at Upcoming Investor Conferences in June June 03, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 17, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates May 06, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer April 29, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer April 17, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference April 04, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering March 27, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Proposed Public Offering March 26, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 25, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome March 25, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) January 17, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024 January 08, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting December 01, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting November 21, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates November 07, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) October 17, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference September 21, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Appoints Ian Smith to its Board of Directors September 20, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress September 05, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates August 07, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference August 02, 2023 From Stoke Therapeutics, Inc. Via Business Wire Tickers STOK < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
